Document:

Exhibit 10.23

 

DIRECTOR NOMINATION
AGREEMENT

 

This Director Nomination Agreement (the
“Agreement”) is made and entered into as of January 15, 2014, by and among Ekso Bionics, Inc. (the “Company”),
Ekso Bionics Holdings, Inc. (f/k/a PN Med Group Inc.)(“Parent”), and CNI Commercial LLC (“CNI”).

 

WHEREAS, pursuant to that certain Amended
and Restated Voting Agreement, dated as of May 30, 2013, by and among the Company and the investors listed on Schedules A and B
thereto (the “Voting Agreement”), CNI has the right to designate two Series B Directors (as defined in the Voting
Agreement) to the Company’s Board of Directors;

 

WHEREAS, the Company intends to enter into
an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Ekso Acquisition Corp., a Delaware
corporation and wholly-owned subsidiary of Parent (“Merger Sub”), will merge with and into the Company and the
Company will become a wholly-owned subsidiary of Parent (the “Merger”);

 

WHEREAS, in connection with the Merger,
the Company intends to terminate the Voting Agreement, and

 

WHEREAS, in consideration of CNI’s
agreement to terminate the Voting Agreement, the Company is willing to grant CNI the director designation rights set forth herein.

 

NOW, THEREFORE, in consideration of the
mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree as follows:

 

1.           Nomination of CNI Director.
From and after the effective time of the Merger as set forth in the Certificate of Merger filed with the Delaware Secretary of
State in connection with the closing of the Merger and until (a) CNI ceases to own or control shares of common stock of Parent,
par value $0.001 per share (the “Common Stock”), representing at least 10% of the issued and outstanding shares
of Common Stock or (b) any of the shares of Common Stock issued to CNI in connection with the Merger cease to be subject to a contractual
lock-up agreement with Parent restricting CNI’s right to sell such shares, whichever is earlier, (i) CNI shall have the right
to nominate for election to the Board of Directors of Parent one (1) director who is reasonably acceptable to the Board of Directors
of Parent (the “CNI Nominee”) and (ii) Parent shall include, and shall use its best efforts to cause the Board of Directors
of Parent (whether acting through a nominating committee of the Board of Directors of otherwise) to include, in the slate of nominees
recommended to the stockholders of Parent for election as a director at any annual or special meeting of stockholders of Parent
at or by which directors of Parent are to be elected, the CNI Nominee.

 

2.           Initial CNI Nominee. The initial
CNI Nominee shall be Dan Boren.

 

3.           Vacancies. Any vacancy on
the Board of Directors of Parent arising through the death, resignation or removal of the CNI Nominee who was nominated to the
Board of Directors of Parent pursuant to Section 1 may be filled by the Board only with a CNI Nominee, and the director so chosen
shall hold office until the next election and until his or her successor is duly elected and qualified, or until his or her earlier
death, resignation or removal.

 

    	 

    	 

    

 

4.           General.

 

(a)  Successors
and Assigns. This Agreement may not be assigned by either party without the prior written consent of the other party.
Subject to the foregoing limitation, all rights hereunder shall inure to the benefit of the parties hereto, their personal or legal
representatives, heirs, successors and permitted assigns.

 

(b)  Entire
Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and thereof
and supersedes all prior and contemplated arrangements and understandings with respect thereto. 

 

(c)  Counterparts.
This Agreement may be signed in counterparts, each of which shall constitute an original and all of which together shall constitute
one and the same Agreement. Signature pages to this Agreement may be delivered by facsimile transmission or in electronic
format as .pdf with the same effect as if the signatory had delivered its original signature page to the receiving party.

 

(d)  Governing Law. This Agreement
and the legal relations hereunder between the parties hereto shall be governed by and construed in accordance with the laws of
the State of Delaware applicable to contracts made and performed therein, without giving effect to the principles of conflicts
of law thereof.

 

(e)  Invalidity of Provision.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid, but if any
provision of this Agreement is held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not
render invalid or unenforceable any other provision of this Agreement.

 

(f)  Further Assurances. Each
party hereto shall do and perform or cause to be done and performed all such further acts and things and shall execute and deliver
all such other agreements, certificates, instruments and documents as any other party hereto reasonably may request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(g)  Amendments and Waivers. The
provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this Agreement may
be waived or modified, with and only with an agreement or consent in writing signed by each of the parties hereto. Waiver by any
party hereto of any breach or default by the other party of any of the terms of this Agreement shall not operate as a waiver of
any other breach or default, whether similar to or different from the breach or default waived. No waiver of any provision of this
Agreement shall be implied from any course of dealing between the parties hereto or from any failure by either party to assert
its or his or her rights hereunder on any occasion or series of occasions.

 

(h)  Enforcement. Each of the
parties hereto agrees that in the event of a breach of any provision of this Agreement, the aggrieved party may elect to institute
and prosecute proceedings in any court of competent jurisdiction to enforce specific performance or to enjoin the continuing breach
of this Agreement. Such remedies, however, shall be cumulative and not exclusive, and shall be in addition to any other remedy
which any party hereto may have.

 

    	 

    	 

    

 

(i)  Jurisdiction. In any judicial
proceeding involving any dispute, controversy or claim arising out of or relating to this Agreement, each of the parties hereto
irrevocably and unconditionally submits to the non-exclusive jurisdiction and venue of any United States District Court located
in the State of Delaware, or of the Court of Chancery of the State of Delaware, and the appellate courts to which orders and judgments
thereof may be appealed. In any such judicial proceeding, each of the parties hereto agrees that in addition to any method for
the service of process permitted or required by such courts, to the fullest extent permitted by law, service of process may be
made by deliver provided pursuant to the directions in Section 4(j). EACH OF THE PARTIES HEREBY WAIVES TRIAL BY JURY IN ANY JUDICIAL
PROCEEDING INVOLVING ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.

 

(j)   Notice. All notice, requests,
demands, waivers, consents and other communications required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been duly given if (i) delivered personally, (ii) mailed by certified or registered mail
with postage prepaid, (iii) sent by next-day or overnight mail or delivery with proof of receipt maintained or (iv) sent
by fax, to the following addresses (or to such other address as the party entitled to notice shall hereafter designate in accordance
with the terms hereof):

 

	 	If to Parent or the Company:	 	Copy to (which copy shall not constitute notice hereunder):
	 	 	 	 
	 	Ekso Bionics Holdings, Inc. or	 	Gottbetter & Partners, LLP
	 	Ekso Bionics, Inc.	 	488 Madison Avenue, 12th Floor
	 	1414 Harbour Way South, Suite 1201	 	New York, NY  10022
	 	Richmond, California 94804	 	Attention:  Adam S. Gottbetter, Esq.
	 	Attn: Nathan Harding, CEO	 	Facsimile:  (212) 400-6901
	 	Facsimile: (510) 927-2647 	 	 
	 	 	 	And
	 	 	 	 
	 	 	 	Nutter, McClennen & Fish LLP
	 	 	 	155 Seaport Blvd.
	 	 	 	Boston, MA 02210
	 	 	 	Attn: Michelle L. Basil
	 	 	 	Facsimile: (617) 310-9477
	 	 	 	 
	 	If to CNI:	 	Copy to (which copy shall not constitute notice hereunder):
	 	 	 	 
	 	CNI Commercial LLC	 	McAfee & Taft
	 	2020 Lonnie Abbott Blvd.	 	10th Floor, Two Leadership Square
	 	Ada, OK 74820	 	211 N. Robinson
	 	Attn:  Patrick Neeley	 	Oklahoma City, OK 73102
	 	Facsimile:  (580) 559-0635	 	Attn: Mike Blake
	 	 	 	Facsimile: (405) 228-7317

 

    	 

    	 

    

 

All such notices, requests, demands, waivers,
consents and other communications shall be deemed to have been received (A) if by personal delivery, on the day delivered,
(B) if by certified or registered mail, on the fifth business day after the mailing thereof, (C) if by next-day or overnight
mail or delivery, on the day delivered, or (D) if by fax, on the day delivered, provided that such delivery is confirmed.

 

5.          Termination.
This Agreement shall terminate upon the earliest of (i) termination of the Merger Agreement, (ii) the date CNI ceases to own or
control shares of Common Stock representing at least 10% of the issued and outstanding shares of Common Stock or (iii) the date
all of the shares of Common Stock issued to CNI in connection with the Merger cease to be subject to a contractual lock-up agreement
with Parent restricting CNI’s right to sell such shares.

 

[Rest of page intentionally
left blank. Signature page follows.]

 

    	 

    	 

    

 

 

IN WITNESS WHEREOF, the parties hereto
have executed this Director Nomination Agreement on the day and year first above written.

 

	 	Ekso Bionics, Inc.
	 	 
	 	By:	/s/ Max Scheder-Bieschin
	 	 	Name: Max Scheder-Bieschin
	 	 	Title: Chief Financial Officer
	 	 
	 	Ekso Bionics Holdings, Inc.
	 	 
	 	By:	/s/ Max Scheder-Bieschin
	 	 	Name: Max Scheder-Bieschin
	 	 	Title: Chief Financial Officer
	 	 
	 	CNI Commercial Llc
	 	 
	 	By:	/s/ David L. Nimmo
	 	 	Name: David L. Nimmo
	 	 	Title: Member RepresentativeExhibit
10.24

 

[Pursuant
to the terms of the warrant, in connection with the merger of Ekso Bionics, Inc. with and into Ekso Acquisition Corp. pursuant
to the Agreement and Plan of Merger and Reorganization dated as of January 15, 2014, the warrants previously issued by Ekso Bionics,
Inc., in the form set forth below, will hereafter represent the right to purchase shares of common stock of Ekso Bionics Holdings,
Inc. and the number of shares and exercise price will be adjusted to reflect the conversion of the common stock of Ekso Bionics,
Inc. into common stock of Ekso Bionics Holdings, Inc.] 

 

THIS WARRANT
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF I933, AS AMENDED
(THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY
AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT
TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS
INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS.

 

WARRANT TO PURCHASE COMMON STOCK OF

EKSO BIONICS, INC.

 

Warrant No.: _____

 

Issued on __________

 

This certifies
that for good and valuable consideration, _____________ (the "Holder"), is entitled, subject to the terms
and conditions of this Warrant, to purchase from Ekso Bionics, Inc., a Delaware corporation (the "Company"),
at any time or from time to time prior to the earlier to occur of (i) a Liquidation Event, (ii) an Initial Public Offering, or
(iii) 5:00p.m. Pacific time on May 20, 2020 (the “Expiration Date"), up to ______ shares of Warrant Stock
(as defined below) (the "Maximum Shares") at a price per share equal to the Warrant Price (as defined below),
upon surrender of this Warrant at the principal offices of the Company, together with a duly executed subscription form in the
form attached hereto as Exhibit 1 and simultaneous payment of the full Warrant Price for the shares of Warrant Stock so
purchased, or if permitted, by an election to net exercise as set forth in Section 2.6, all in accordance with the terms hereof.
The Warrant Price and the number and character of shares of Warrant Stock purchasable under this Warrant are subject to adjustment
as provided herein.

 

This Warrant is one of a series
of Warrants issued pursuant to that certain Series B Preferred Stock and Warrant Purchase Agreement, dated as of May 20,2013, by
and among the Company and certain purchaser of Series B Preferred Stock, as amended from time to time (the "Purchase
Agreement").

 

1.           DEFINITIONS.
The following definitions shall apply for purposes of this Warrant:

 

1.1         "Holder"
means any person who shall at the time be the registered holder of this Warrant.

 

    	 

    	 

    

 

1.2
       “Initial Public Offering" means the initial firm commitment underwritten public offering of the Company
pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the "Securities Act”),
covering the offer and sale of the Company's Common Stock for the account of the Company.

 

1.3          “Liquidation
Event” shall mean any voluntary or involuntary liquidation, dissolution or winding up of the Company or Deemed Liquidation
Event (as defined in the Company's Restated Ce1tificate of Incorporation or any successor provision thereof).

 

1.4          "Rights
Agreement" means that certain Amended and Restated Investors' Rights Agreement, dated as of May 20, 2013, by and among
the Company and certain Investors identified therein, as amended from time to time.

 

1.5         "Warrant
Price" means Two Dollars and Ten Cents ($2.10) per share. The Warrant Price is subject to adjustment as provided herein.

 

1.6         "Warrant
Stock" means the Company's Common Stock, $0.001 par value per share. The number and character of shares of Warrant
Stock are subject to adjustment as provided herein and the term "Warrant Stock" shall include stock and
other securities and prope1iy at any time receivable or issuable upon exercise of this Warrant in accordance with its terms.

 

2.           EXERCISE.

 

2.1         Method
of Exercise. Subject to the terms and conditions of this Warrant, the Holder may exercise this Warrant in whole or in part,
at any time or from time to time, on any business day before the Expiration Date, for up to _________ shares of Warrant Stock,
by surrendering this Warrant at the principal offices of the Company, with the subscription form attached hereto duly executed
by the Holder, and payment of an amount equal to the product obtained by multiplying (i) the number of shares of Warrant Stock
to be purchased by the Holder by (ii) the Warrant Price or adjusted Warrant Price therefor, if applicable, as determined in accordance
with the terms hereof, or, if applicable, an election to net exercise the Warrant as provided in Section 2.6 for the number of
shares to be acquired in connection with such exercise. Holder may deliver the subscription form attached hereto duly executed
by Holder in order to exercise this Warrant in connection with an Initial Public Offering or a Liquidation Event, with the exercise
and payment to be contingent upon consummation of the transaction.

 

2.2         Form
of Payment. Payment may be made by (a) check payable to the Company's order, (b) wire transfer of funds to the Company, (c)
by net exercise as provided in Section 2.6, or (d) any combination of the foregoing.

 

2.3         Partial
Exercise. Upon a partial exercise of this Warrant the number of shares of Warrant Stock issuable upon exercise of this Warrant
immediately prior to such exercise shall be reduced by the aggregate number of shares of Warrant Stock issued upon such exercise
of this Warrant.

 

2.4         No
Fractional Shares. No fractional shares may be issued upon any exercise of this Warrant, and any fractions shall be rounded
down to the nearest whole number of shares. If upon any exercise of this Warrant a fraction of a share would otherwise result,
the Company will pay the cash value of any such fractional share.

 

    	 

    	 

    

 

2.5         Restrictions
on Exercise. This Warrant may not be exercised if the issuance of the Warrant Stock upon such exercise would constitute a violation
of any applicable federal or state securities laws or other laws or regulations. As a condition to the exercise of this Warrant,
the Holder shall execute the subscription form attached hereto as Exhibit 1, confirming and acknowledging that the representations
and warranties of the Holder set forth in Section 6 of this Warrant are true and correct as of the date of exercise.

 

2.6         Net Exercise Election.

 

2.6.1
   Holder may elect to convert all or any portion of this Warrant, without the payment by Holder of any additional consideration
(other than surrender of the right to acquire shares of Warrant Stock as set forth in this Section 2.6), by the surrender of this
Warrant to the Company, with the net exercise election selected in the subscription form attached hereto, duly executed by Holder,
into up to the number of shares of Warrant Stock that is obtained under the following formula:

 

X = Y (A-B)

            A

 

	where	X =	the net number of shares of Warrant Stock to be issued
to Holder pursuant to a net exercise of this Warrant effected pursuant to this Section 2.6.

 

		Y =	the gross number of shares of Warrant Stock for which
the Warrant is exercised (not to exceed the Maximum Shares less all shares previously issued or canceled upon prior exercises
of this Warrant) before taking into account shares surrendered pursuant to this Section 2.6 in payment of the Warrant Price for
the shares subject to exercise.

 

		A =	the fair market value of one share of Warrant Stock,
determined at the time of such net exercise as set forth in the last paragraph of this Section 2.6.

 

		B =	the Warrant Price.

 

The Company will promptly respond in writing to an
inquiry by Holder as to the then current fair market value of one share of Warrant Stock.

 

2.6.2    
For purposes of the above calculation, fair market value of one share of Warrant Stock shall be determined by the Company's Board
of Directors in good faith;  provided however, that if on the relevant exercise date for which such value must be
determined, the Warrant is being exercised in connection with the Company's Initial Public Offering, the fair market value shall
be the per-share offering price to the public as set forth in the Company's final prospectus filed with the Securities and Exchange
Commission.

 

3.         ISSUANCE
OF STOCK. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the
date that a duly completed and executed Form of Subscription in the form attached hereto as Exhibit 1 and payment of the
full Warrant Price in accordance with this Warrant have been delivered to the Company, whereupon the person entitled to receive
the shares of Warrant Stock issuable upon such exercise shall be treated for all purposes as the holder of record of such shares
as of the close of business on such date. As soon as practicable on or after such date, but conditioned upon the receipt of this
Warrant by the Company, the Company shall issue and deliver to the person or persons entitled to receive the same a certificate
or certificates for the number of whole shares of Warrant Stock issuable upon such exercise.

 

    	 

    	 

    

 

4.         EARLY
EXPIRATION. This Warrant shall automatically expire and be of no further force and effect without any action by
the Company or the Holder immediately prior to the effective date of a Liquidation Event or Initial Public Offering. If the Company
proposes at any time to effect a Liquidation Event or Initial Public Offering, then at least thirty (30) days prior to the effective
date of such event the Company shall mail to the Holder a notice (the "Transaction Notice") specifying
the date on which the Liquidation Event or Initial Public Offering is anticipated to become effective.

 

5.         ADJUSTMENT
PROVISIONS. The number and character of shares of Warrant Stock issuable upon exercise of this Warrant (or any shares of
stock or other securities or property at the time receivable or issuable upon exercise of this Warrant) and the Warrant Price therefor,
are subject to adjustment upon the occurrence of the following events between the date this Warrant is issued and the date it is
exercised:

 

5.1         Adjustment
for Stock Splits, Stock Dividends, Recapitalizations, etc. The Warrant Price of this Warrant and the number of shares of Warrant
Stock issuable upon exercise of this Warrant (or any shares of stock or other securities at the time issuable upon exercise of
this Warrant) shall each be proportionally adjusted to reflect any stock dividend, stock split, reverse stock split, reclassification,
recapitalization or other similar event affecting the number of outstanding shares of Warrant Stock (or such other stock or securities).

 

5.2         Adjustment
for Reorganization, Consolidation, Merger. Other than any reorganization, consolidation or merger that constitutes a Liquidation
Event, in case of any reorganization of the Company (or of any other entity, the stock or other securities of which are at the
time receivable on the exercise of this Warrant), after the date of this Warrant, or in case, after such date, the Company (or
any such entity) shall consolidate with or merge into another entity, convey all or substantially all of its assets to another
entity and then distribute the proceeds to its equity holders or convert the Company into another entity (such as a limited liability
company), then, and in each such case, the Holder, upon the exercise of this Warrant (as provided in Section 2), at any time after
the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in lieu of the stock
or other securities and property receivable upon the exercise of this Warrant prior to such consummation, the stock or other securities
or property to which the Holder would have been entitled upon the consummation of such reorganization, consolidation, merger or
conveyance if the Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment as provided in
this Warrant, and the successor or purchasing entity in such reorganization, consolidation, merger or conveyance (if other than
the Company) shall duly execute and deliver to the Holder a supplement hereto acknowledging such successor's obligations under
this Warrant; and in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or
property receivable upon the exercise of this Warrant after the consummation of such reorganization, consolidation, merger or conveyance.

 

5.3         No
Change Necessary. The form of this Warrant need not be changed because of any adjustment in the Warrant Price or in the number
of shares of Warrant Stock issuable upon its exercise.

 

5.4         Certificate
of Adjustment. When any adjustment is required to be made in the Warrant Price or the number of shares of Warrant Stock issuable
upon exercise of this Warrant, the Company shall promptly mail to the Holder a certificate setting forth the Warrant Price after
such adjustment and setting forth a brief statement of the facts requiring such adjustment. Such certificate shall also set fo1th
the kind and amount of stock or other securities or property into which this Warrant shall be exercisable following the occurrence
of any of the events specified in this Section 5.

 

    	 

    	 

    

 

6.         
[INTENTIONALLY OMITTED]

 

7.         
NO RIGHTS OR LIABILITIES AS STOCKHOLDER. This Warrant does not by itself entitle the Holder to any voting
rights or other rights as a stockholder of the Company. In the absence of affirmative action by the Holder to purchase Warrant
Stock by exercise of this Warrant, no provisions of this Warrant, and no enumeration herein of the rights or privileges of the
Holder, shall cause the Holder to be a stockholder of the Company for any purpose.

 

8.       
  ATTORNEYS' FEES. In the event any party is required to engage the services of any attorneys for the purpose
of enforcing this Warrant, or any provision thereof, the prevailing party shall be entitled to recover its reasonable expenses
and costs in enforcing this Warrant, including attorneys' fees.

 

9.         
TRANSFER. Except as expressly provided hereunder, neither this Warrant nor any rights hereunder may be assigned,
conveyed or transferred by Holder, in whole or in part, without the Company's prior written consent, which the Company may withhold
in its sole discretion. The rights and obligations of the Company and the Holder under this Warrant shall be binding upon and benefit
their respective permitted successors, assigns, heirs, administrators and transferees.

 

10.       
GOVERNING LAW. This Warrant shall be governed by, and construed in accordance with, the laws of the State of Delaware,
excluding choice of law or conflict of law principles.

 

11.       
HEADINGS. The headings and captions used in this Warrant are used only for convenience and are not to be considered
in construing or interpreting this Warrant. All references in this Warrant to sections and exhibits shall, unless otherwise provided,
refer to sections hereof and exhibits attached hereto, all of which exhibits are incorporated herein by this reference.

 

12.   
    NOTICES. All notice, requests, and other communications given, made or delivered pursuant to
this Warrant shall be in writing and shall be deemed effectively given, made or delivered upon the earlier of actual receipt
or: (a) personal delivery to the party to be notified; (b) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (c) one (1) business day after the business day of deposit with a
nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt,
when addressed to the patty to be notified at the address indicated for such patty on the signature page hereto or, in the
case of the Company, at 1414 Harbour Way S., Ste. 201, Richmond, CA 94804, Attn.: President and Chief Executive Officer, and
when addressed to Holder at the address set fot1h next to Holder's signature on this Warrant, or at such other address as any
patty or the Company may designate by giving ten (10) days' advance written notice to all other parties.

 

13.       AMENDMENT;
WAIVER. Any term of this Warrant may be amended, and the observance of any term of this Warrant may be waived (either generally
or in a pat1icular instance and either retroactively or prospectively) with the consent of holders of Warrants issued pursuant
to the Purchase Agreement representing at least seventy percent (70%) of the shares of Warrant Stock, and any amendment or waiver
effected in accordance with this Section shall be binding upon Holder and all Holders of Warrants issued pursuant to the Purchase
Agreement.

 

14.        SEVERABILITY.
If one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision(s) shall be excluded
from this Warrant and the balance of the Warrant shall be interpreted as if such provision(s) were so excluded and shall be enforceable
in accordance with its terms.

 

    	 

    	 

    

 

15.       
TERMS BINDING. By acceptance of this Warrant, the Holder accepts and agrees to be bound by all the terms and conditions
of this Warrant.

 

[Remainder of Page Intentionally Left Blank]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Warrant as of the date first above written.

 

	THE COMPANY:	 
	 	 
	EKSO BIONICS, INC.	 
	 	 	 
	By: 	 	 
	Name: 	 	 
	Title: 	 	 
	 	 	 
	AGREED AND ACKNOWLEDGED	 
	 	 	 
	THE HOLDER:	 
	 	 	 
	By: 	 	 
	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]